Furthermore, impairments of brain insulin levels/signaling and glucose metabolism in type 2 diabetes and AD further suggest that an effective treatment strategy for one disorder may be also beneficial in the other [7], obviously, based on the convergence of signaling pathways of insulinotropic and neuroprotective therapies. The gene discussed is INS; the disease is type 2 diabetes mellitus.